Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Self-adjusting synthetic gene circuit for correcting insulin resistance

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Genetically Encoded Synthetic Beta Cells for Insulin Biosynthesis and Release under Hyperglycemic Conditions

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

Hydrophobicity Regulation of Energy Acceptors Confined in Mesoporous Silica Enabled Reversible Activation of Optogenetics for Closed-Loop Glycemic Control

Genetic-code-expanded cell-based therapy for treating diabetes in mice

Synthetic gene circuits for cell state detection and protein tuning in human pluripotent stem cells

Customizable gene sensing and response without altering endogenous coding sequences

Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

Engineering Synthetic CopT/A-Based Genetic Biosensors for miRNA Imaging and Functional Gene Regulation

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

Glucose-activated switch regulating insulin analogue secretion enables long-term precise glucose control in type 1 diabetes mice

Clinically-driven design of synthetic gene regulatory programs in human cells

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation

A Gene‐Switch Platform Interfacing with Reactive Oxygen Species Enables Transcription Fine‐Tuning by Soluble and Volatile Pharmacologics and Food Additives

Insertion of a synthetic switch into insulin provides metabolite-dependent regulation of hormone-receptor activation

A chemical-genetic approach to study G protein regulation of β cell function in vivo

Genetically Engineered K Cells Provide Sufficient Insulin to Correct Hyperglycemia in a Nude Murine Model.

Ultrashort‐Peptide‐Responsive Gene Switches for Regulation of Therapeutic Protein Expression in Mammalian Cells

Deep mutational scanning of the human insulin receptor ectodomain to inform precision therapy for insulin resistance